

Codupha Central Pharmaceutical Joint Stock Company

Financial Statements

For the financial period ended September 30, 2026

**CÔNG TY CỔ PHẦN DƯỢC
PHẨM TRUNG ƯƠNG
CODUPHA**

Digitally signed by CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG
CODUPHA
DN: OID.0.9.2342.19200300.100.1.1=MST:0300483319, CN=CÔNG TY CỔ
PHẦN DƯỢC PHẨM TRUNG ƯƠNG CODUPHA, S=Hồ Chí Minh, C=VN
Reason: I am the author of this document
Location: your signing location here
Date: 2026-10-19 13:43:22
Foxit PhantomPDF Version: 9.7.1

Codupha Central Pharmaceutical Joint Stock Company

Statement of Financial Position for the Nine-Month Period Ended 30 September 2026

	Co de	Note	30/09/2026 VND	1/1/2026 VND (As Restated)
ASSETS				
Current assets (100 = 110 + 120 + 130 + 140 + 160)	100		2,233,681,365,290	2,226,223,923,911
Cash and cash equivalents	110	5	83,340,869,391	30,439,123,602
Cash	111		83,340,869,391	30,439,123,602
Cash equivalents	112			
Short-term financial investments	120		307,479,452	300,000,000
Short-term Held-to-Maturity Investments	123		307,479,452	300,000,000
Accounts receivable – short-term	130		1,113,737,131,757	1,238,248,931,791
Accounts receivable from customers	131	7	1,084,678,970,963	1,192,482,025,839
Prepayments to suppliers	132	8	51,821,509,528	14,239,289,949
Other receivables	135	9	39,263,750,372	81,417,310,952
Allowance for doubtful debts	136	10	(62,027,099,106)	(49,889,694,949)
Inventories	140		1,011,437,703,553	944,901,542,903
Inventories	141	11	1,013,962,535,431	945,960,367,278
Allowance for inventories	142		(2,524,831,878)	(1,058,824,375)
Other current assets	160		24,858,181,137	12,334,325,615
Short-term deferred expenses	161		1,352,472,634	45,993,487
Deductible value added tax	162		12,640,476,734	11,620,627,648
Taxes and others receivable from the State	163		2,765,231,769	167,318,390
Other current assets	165	12	8,100,000,000	500,386,090

Codupha Central Pharmaceutical Joint Stock Company

Statement of Financial Position for the Nine-Month Period Ended 30 September 2026

	Co de	Note	30/09/2026 VND	1/1/2026 VND (As Restated)
Long-term assets (200 = 210 + 220 + 240 + 250 + 260 + 270)	200		177,863,183,615	187,458,152,022
Accounts receivable – long-term	210		776,000,000	650,000,000
Other long-term receivables	215	9b	776,000,000	650,000,000
Fixed assets	220		141,986,795,400	151,369,362,935
Tangible fixed assets	221	13	68,350,624,229	75,575,337,090
Cost	222		186,385,494,388	185,544,195,499
Accumulated depreciation	223		(118,034,870,159)	(109,968,858,409)
Intangible fixed assets	227	14	73,636,171,171	75,794,025,845
Cost	228		97,704,403,845	97,704,403,845
Accumulated depreciation	229		(24,068,232,674)	(21,910,378,000)
Long-term work in progress	250		381,000,000	540,900,000
Construction in progress	252	15	381,000,000	540,900,000
Long-term financial investments	260	6	32,992,893,387	32,992,893,387
Investments in associates	262		3,520,408,664	3,520,408,664
Equity investments in other entities	263		29,472,484,723	29,472,484,723
Other long-term assets	270		1,726,494,828	1,904,995,700
Long-term deferred expenses	271	16	524,492,956	1,904,995,700
Deferred tax assets	272	17	1,202,001,872	-
TOTAL ASSETS (280 = 100 + 200)	280		2,411,544,548,905	2,413,682,075,933

Codupha Central Pharmaceutical Joint Stock Company

Statement of Financial Position for the Nine-Month Period Ended 30 September 2026

	Co de	Note	30/09/2026 VND	1/1/2026 VND (As Restated)
RESOURCES				
LIABILITIES (300 = 310 + 330)	300		2,178,915,523,563	2,186,401,045,317
Current liabilities	310		2,149,781,824,541	2,157,241,113,385
Accounts payable to suppliers	311	18	979,660,524,675	1,145,294,886,764
Advances from customers	312	19	108,663,858,403	26,000,290,269
Dividends payable	313		119,098,976	7,311,946,477
Taxes and others payable to the State – short-term	314	20	2,383,876,237	518,739,572
Payable to employees	315		2,324,196,742	6,440,080,995
Accrued expenses	316	21	5,754,672,567	3,453,501,617
Deferred revenue	319		49,643,929	49,643,929
Other payables – short-term	320	22	12,639,152,751	4,725,734,740
Short-term borrowings	321	23	1,036,844,659,518	963,446,289,022
Bonus and welfare funds	323	24	1,342,140,743	-
Long-term liabilities	330		29,133,699,022	29,159,931,932
Long-term deferred revenue	337		111,699,022	148,931,932
Other payables – long-term	338		22,000,000	11,000,000
Long-term borrowings	339	23	29,000,000,000	29,000,000,000
EQUITY	400		232,629,025,342	227,281,030,616
Share capital	411	26	182,700,000,000	182,700,000,000
- Ordinary shares with voting rights	411a		182,700,000,000	182,700,000,000
Other Owners' Equity	414			
Repurchased own shares	415		(586,200,000)	(586,200,000)
Investment and development fund	418		9,071,115,794	9,071,115,794
Retained profits	420		41,444,109,548	36,096,114,822
- Retained profits brought forward	420a		20,245,287,325	12,643,451,512
- Retained profit for the current period	420b		21,198,822,223	23,452,663,310
TOTAL RESOURCES (440 = 300 + 400)	440		2,411,544,548,905	2,413,682,075,933



Pham Thi Mai Huong
General Director

Approver

Ngo Thi Bich Thao
Responsible for accounting and financial reporting

Authorized on October 19, 2026

Prepared by

Chu Thi Bich Hong
Deputy Finance and Accounting Director

Codupha Central Pharmaceutical Joint Stock Company

Statement of Income for the Nine-Month Period Ended 30 September 2026

ITEMS	Code	Note	The third quarter ended		Nine-month period ended	
			30/ 09/ 2026	30 /09/ 2025	30 /09/ 2026	30 /09/ 2025
			VND	VND	VND	VND
Revenue from sales of goods and provision of services	01		689,453,454,189	773,318,283,979	2,002,418,543,588	2,257,279,751,388
Revenue deductions	02		1,931,455,314	5,996,770,217	21,778,982,556	13,413,391,597
Net revenue from sales of goods and provision of services (10 = 01 - 02)	10	28	687,521,998,875	767,321,513,762	1,980,639,561,032	2,243,866,359,791
Cost of sales	11	29	625,481,310,042	714,916,406,531	1,800,721,632,293	2,092,536,428,350
Gross profit from sales of goods and provision of services (20 = 10 - 11)	20		62,040,688,833	52,405,107,231	179,917,928,739	151,329,931,441
Financial income	22	30	4,177,070,619	9,965,741,351	20,573,105,647	24,061,965,558
Financial expenses	23	31	20,458,694,079	13,107,106,062	57,897,895,477	40,320,131,744
In which: Interest expense	24		20,458,694,079	11,423,458,890	55,533,279,847	33,184,367,292
Selling expenses	25	32	30,707,845,586	30,810,329,886	89,653,835,488	86,816,537,233
General and administration expenses	26	33	4,524,129,071	10,874,340,540	24,782,284,120	26,343,535,685
Net operating profit {30 = 20 + 22 - 23 - (25 + 26)}	30		10,527,090,716	7,579,072,094	28,157,019,301	21,911,692,337
Other income	31	35	717,164,962	4,078,456,851	859,763,923	4,546,473,468
Other expenses	32	36	189,242,870	135,394,881	2,366,305,135	427,412,725
Results of other activities (40 = 31 - 32)	40		527,922,092	3,943,061,970	(1,506,541,212)	4,119,060,743
Accounting profit before tax (50 = 30 + 40)	50		11,055,012,808	11,522,134,064	26,650,478,089	26,030,753,080
Income tax expense – current	51	37	1,889,740,358	2,331,505,789	6,653,657,738	5,099,951,775
Income tax benefit – deferred	52		-	-	(1,202,001,872)	-
Net profit after tax (60 = 50 - 51)	60		9,165,272,450	9,190,628,275	21,198,822,223	20,930,801,305
Basic earnings per share	70				978	879

Authorized on October 19, 2026



Approver

Phạm Thị Mai Hương
General Director

Ngo Thi Bích Thao
Responsible for accounting and
financial reporting

Prepared by

Chu Thi Bích Hồng
Deputy Finance and Accounting Director

Codupha Central Pharmaceutical Joint Stock Company

Statement of Cash Flows for the Nine-Month Period Ended September 30, 2026

		Nine-month period ended	
		30 /09 /2026	30 /09 /2025
	Code Note	VND	VND
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax	01	26,650,478,089	26,030,753,080
Điều chỉnh cho các khoản			
Depreciation and amortisation	02	10,223,866,424	10,480,687,156
Allowances and provisions	03	13,603,411,660	8,700,974,839
Exchange losses/(gains) arising from revaluation of monetary items denominated in foreign currencies	04	(1,686,949,627)	(2,893,627,717)
Profits from investing, financing activities	05	(33,995,119)	(732,775,145)
Interest expense	06	55,533,279,847	33,184,367,292
Other Adjustments	07	-	117,465,809
Operating profit before changes in working capital	08	104,290,091,274	74,887,845,314
Change in receivables	09	109,309,046,007	27,146,991,126
Change in inventories	10	(68,002,168,153)	(26,880,122,589)
Change in payables and other liabilities	11	(79,763,389,789)	(127,476,895,776)
Change in deferred expenses	12	74,023,597	236,809,637
Interest paid	14	(52,840,857,907)	(30,147,247,358)
Income tax paid	15	(4,806,510,522)	(4,317,306,074)
Other payments for operating activities	17	(4,248,841,383)	(2,880,089,229)
Net cash flows from operating activities	20	4,011,393,124	(89,430,014,949)
CASH FLOWS FROM INVESTING ACTIVITIES			
Payments for additions to fixed assets	21	(681,398,889)	(317,855,455)
Proceeds from disposals of fixed assets	22	2,222,222	758,826,598
Payments for placement of term deposits with banks	23	(8,100,000,000)	-
Collections on investments in other entities	26	-	6,602,534,191
Receipts of interests	27	24,293,445	23,626,677
Net cash flows from investing activities	30	(8,754,883,222)	7,067,132,011

Codupha Central Pharmaceutical Joint Stock Company

Statement of Cash Flows for the Nine-Month Period Ended September 30, 2026

	Code	Note	Nine-month period ended	
			30 /09 /2026 VND	30 /09 /2025 VND
CASH FLOWS FROM FINANCING ACTIVITIES				
Proceeds from borrowings	33		2,206,326,140,137	2,124,158,443,903
Payments to settle loan principals	34		(2,132,927,769,641)	(2,024,991,310,247)
Payments of dividends	36		(16,250,691,000)	(16,372,188,000)
Net cash flows from financing activities	40		57,147,679,496	82,794,945,656
Net cash flows during the period (50 = 20 + 30 + 40)	50		52,404,189,398	432,062,718
Cash and cash equivalents at the beginning of the period	60		30,939,509,692	20,839,104,211
Effect of exchange rate fluctuations on cash and cash equivalents	61		(2,829,699)	35,823,694
Cash and cash equivalents at the end of the period (70 = 50 + 60 + 61)	70		83,340,869,391	21,306,990,623



Pham Thi Mai Huong
General Director

Approver

Ngo Thi Bich Thao
Responsible for accounting and
financial reporting

Authorized on October 19, 2026

Prepared by

Chu Thi Bich Hong
Deputy Finance and Accounting Director

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

1. Reporting entity

(a) Ownership structure

Codupha Central Pharmaceutical Joint Stock Company (“the Company”) is incorporated as a joint stock company in Vietnam.

(b) Principal activities

The principal activities of the Company are wholesale and retail trading of pharmaceuticals, medical instruments and supplies, cosmetics, and sanitary products.

(c) Normal operating cycle

The normal operating cycle of the Company is generally within 12 months.

(d) Company structure

At September 30, 2026, the Company had 363 employees (January 1, 2026: 369 employees).

At September 30, 2026, the Company's dependent accounting branches and representative office were as follows:

- Codupha Central Pharmaceutical Joint Stock Company - Hanoi Branch – No. 16, Lot C2/NO, Nam Trung Yen Area, Yen Hoa Ward, Hanoi City, Vietnam.
- Codupha Central Pharmaceutical Joint Stock Company - Hai Phong Branch – No. 18, Lot 11B, Tran Van Giang Street, Hai An Ward, Hai Phong City, Vietnam.
- Codupha Central Pharmaceutical Joint Stock Company - Vinh City Branch – No. 182, Thang Long Street, Hamlet 14, Vinh Hung Ward, Nghe An Province, Vietnam.
- Codupha Central Pharmaceutical Joint Stock Company - Central Region Branch – Street No. 2, Hoa Khanh Industrial Park, Lien Chieu Ward, Da Nang City, Vietnam.
- Codupha Central Pharmaceutical Joint Stock Company - Central Highlands Branch – No. 24, Nguyen Trac Street, Buon Ma Thuot Ward, Dak Lak Province, Vietnam.
- Codupha Central Pharmaceutical Joint Stock Company - Can Tho Branch – No. 132A, Extended Nguyen Van Cu Street, Tan An Ward, Can Tho City, Vietnam.
- Representative Office of Codupha Central Pharmaceutical Joint Stock Company - An Giang – No. 57, Tran Hung Dao Street, Long Xuyen Ward, An Giang Province, Vietnam.

2. Basis of preparation

(a) Statement of compliance

The interim financial statements have been prepared in accordance with Vietnamese Accounting Standards, the Vietnamese Accounting System for Enterprises and the relevant statutory requirements applicable to interim financial reporting.

(b) Basis of measurement

The interim financial statements, except for the statement of cash flows, are prepared on the accrual basis using the historical cost concept. The statement of cash flows is prepared using the indirect method.

(c) Annual accounting period

The annual accounting period of the Company is from 1 January to 31 December.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(d) Accounting and presentation currency

The Company's accounting currency is Vietnam Dong ("VND"), which is also the currency used for financial statement presentation purpose.

3. Adoption of new guidance on accounting system for enterprises

On 27 October 2025, the Ministry of Finance issued Circular No. 99/2025/TT-BTC providing guidance on the Vietnamese Accounting System for Enterprises ("Circular 99"). Circular 99 replaces the previous guidance on Vietnamese Accounting System for Enterprises under Circular No. 200/2014/TT-BTC dated 22 December 2014 ("Circular 200") and other circulars amending and supplementing Circular 200. Circular 99 is effective from 1 January 2026 and applicable for annual accounting periods beginning on or after 1 January 2026.

The Company has adopted the applicable requirements of Circular 99 effective from 1 January 2026 on a prospective basis, with reclassification of certain corresponding items, unless Circular 99 specifically stipulates otherwise.

4. Summary of significant accounting policies

The following significant accounting policies have been adopted by the Company in the preparation of these interim financial statements.

The accounting policies that have been adopted by the Company in the preparation of these interim financial statements are consistent with those adopted in the preparation of the latest annual financial statements, except for those described in Note 3.

(a) Foreign currency transactions

Transactions in currencies other than VND during the period have been translated into VND at rates approximating actual rates of exchange ruling at the transaction dates.

Monetary assets and liabilities denominated in currencies other than VND are translated into VND at the average of the account transfer buying rates and selling rates at the end of the accounting period quoted by the commercial bank where the Company most frequently conducts transactions. Demand deposits denominated in currencies other than VND are translated into VND at the average of the account transfer buying rates and selling rates at the end of the accounting period quoted by the commercial bank where the Company maintains the demand deposit accounts.

All foreign exchange differences are recorded in the statement of income.

(b) Cash

Cash comprises cash balances and demand deposits.

(c) Investments

(i) Held-to-maturity investments

Held-to-maturity investments are those that the Company's management has the intention and ability to hold until maturity. Held-to-maturity investments include term deposits at bank. These investments are initially recognised at cost. Subsequent to initial recognition, the investments are stated at amortised costs less allowance for held-to-maturity investments.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(ii) Investments in an associate

For the purpose of these financial statements, investments in an associate are initially recognised at cost which includes purchase price plus any directly attributable transaction costs. Subsequent to initial recognition, these investments are stated at cost less allowance for impairment.

An allowance is made for impairment of investment if the investee has suffered a loss which may cause the Company to lose its invested capital, unless there is evidence that the value of the investment has not been diminished. The allowance is reversed if the investee subsequently made a profit that offsets the previous loss for which the allowance had been made. An allowance is reversed only to the extent that the investment's carrying amount does not exceed the carrying amount that would have been determined if no allowance had been recognised.

(iii) Investments in other entities

Investments in other entities comprises investments in equity instruments of other entities that the Company does not have control, joint control or significant influence over the investees. These investments are initially recognised at cost which include purchase price plus any directly attributable transaction costs. Subsequent to initial recognition, these investments are stated at cost less allowance for impairment.

An allowance is made for impairment of investment if the investee has suffered a loss which may cause the Company to lose its invested capital, unless there is evidence that the value of the investment has not been diminished. The allowance is reversed if the investee subsequently made a profit that offsets the previous loss for which the allowance had been made. An allowance is reversed only to the extent that the investment's carrying amount does not exceed the carrying amount that would have been determined if no allowance had been recognised.

(d) Accounts receivable

Trade and other receivables are stated at cost less allowance for doubtful debts. An allowance for doubtful debts is made for receivables that are overdue or deemed likely to be uncollectible.

The allowance for overdue trade and other receivables is assessed on a case-by-case basis based on available evidence at the end of the accounting period regarding recoverability, aging analysis and specific provisioning rates as below:

	Allowance percentage
Past due 6 months – 1 year	30%
Past due 1 – 2 years	50%
Past due 2 – 3 years	70%
Past due more than 3 years	100%

Trade and other receivables that are not past due but are assessed as unlikely to be collected based on available evidence at the end of the accounting period shall have an allowance provided on a case-by-case basis.

(e) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined on the specific identification method and includes all costs incurred in bringing the inventories to their present location and condition. Net realisable value is the estimated selling price of inventory items, less the estimated costs of completion and estimated costs to sell.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(f) Tangible fixed assets

(i) Cost

Tangible fixed assets are stated at cost less accumulated depreciation. The initial cost of a tangible fixed asset comprises its purchase price, including import duties, non-refundable purchase taxes and any directly attributable costs of bringing the asset to its working condition for its intended use and adjustments arising from the revaluation of assets upon the Company's equitisation as approved by the relevant authorities. Expenditure incurred after tangible fixed assets have been put into operation, such as repair, maintenance and overhaul cost, is charged to the statement of income in the period in which the cost is incurred. In situations where it can be clearly demonstrated that the expenditure has resulted in an increase in the future economic benefits expected to be obtained from the use of tangible fixed assets beyond their originally assessed standard of performance, the expenditure is capitalised as an additional cost of tangible fixed assets.

(ii) Depreciation

Depreciation is computed on a straight-line basis over the estimated useful lives of tangible fixed assets. The estimated useful lives are as follows:

▪ buildings and structures	6 – 40 year
▪ machinery and equipment	3 – 12 year
▪ motor vehicles	10 year
▪ office equipment	3 – 12 year

(g) Intangible fixed assets

(i) Land use rights

Land use rights are stated at cost less accumulated amortisation. The initial cost of a land use right comprises its transfer price and any directly attributable costs incurred in conjunction with securing the land use rights. Amortisation is computed on a straight-line basis over a period ranging from 30 to 50 years for land use rights with definite term. Land use rights with indefinite term are not amortised.

(ii) Software

Cost of acquiring new software, which is not an integral part of the related hardware, is capitalised and treated as an intangible asset. Software cost is amortised on a straight-line basis over 10 years.

(h) Construction in progress

Construction in progress represents the costs of tangible and intangible fixed assets which have not been fully completed. No depreciation is provided for construction in progress during the period of construction and installation.

(i) Long-term deferred expenses

Tools and instruments

Tools and instruments include assets held for use by the Company in the normal course of business whose costs of individual items are less than VND30 million and therefore not qualified for recognition as fixed assets under prevailing regulation. Cost of tools and instruments are amortised on a straight-line basis over a period ranging from 1 to 3 years.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(j) Trade and other payables and accruals

Trade and other payables and accruals are stated at their cost.

(k) Dividends payable

Dividends payable are recognised at the date when the General Meeting of Shareholders of the Company resolved to distribute dividends to shareholders.

(l) Provisions

A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

Severance allowance

Under the Vietnamese Labour Code, when an employee who has worked for 12 months or more ("the eligible employees") voluntarily terminates his/her labour contract, the employer is required to pay the eligible employee severance allowance calculated based on years of service and employee's compensation at termination. Provision for severance allowance has been provided based on employees' years of service and their average salary for the six-month period prior to the end of the accounting period. For the purpose of determining the number of years of service by an employee, the period for which the employee participated in and contributed to unemployment insurance in accordance with prevailing laws and regulations and the period for which severance allowance has been paid by the Company are excluded.

(m) Share capital

(i) Ordinary shares

Ordinary shares are recognised at issuance price less incremental costs directly attributable to the issue of shares, net of tax effects. Such costs are recognised as a deduction from share premium.

(ii) Repurchase and reissue of ordinary shares (repurchased own shares/treasury shares)

Before 1 January 2021, When shares recognised as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of tax effects, is recognised as a reduction from equity. Repurchased shares before 1 January 2021 are classified as treasury shares under equity.

This change in accounting policy has been applied prospectively from 1 January 2021 due to change in applicable laws and regulations on buying back shares.

When treasury/repurchased own shares are sold or reissued subsequently, cost of the reissued shares is determined on a weighted average basis. Any difference between the amount received and the cost of the shares reissued is presented within share premium.

(n) Taxation

Income tax on the profit for the period comprises current and deferred tax. Income tax is recognised in the statement of income except to the extent that it relates to items recognised directly to equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted at

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

the end of the accounting period, and any adjustment to tax payable in respect of previous periods.

Deferred tax is provided using the statement of financial position method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amounts of assets and liabilities using the tax rates enacted or substantively enacted at the end of the accounting period.

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilised. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

(o) Revenue and other incomes

(i) Goods sold

Revenue from the sale of goods is recognised in the statement of income when the significant risks and rewards of ownership have been transferred to the buyer. No revenue is recognised if there are significant uncertainties regarding recovery of the consideration due or the possible return of goods.

(ii) Services rendered

Revenue from services rendered is recognised in the statement of income in proportion to the stage of completion of the transaction. The stage of completion is assessed by reference to surveys of work performed. No revenue is recognised if there are significant uncertainties regarding recovery of the consideration due.

(iii) Rental income

Rental income from leased property is recognised in the statement of income on a straight-line basis over the term of the lease.

(iv) Interest income

Interest income is recognised on a time proportion basis with reference to the principal outstanding and the applicable interest rate. However, interest income is not recognised for held-to-maturity investments that have been provided allowance for impairment due to unlikelihood of recovery.

(v) Dividend income

Dividend income from shares that have been registered and centrally deposited at the Vietnam Securities Depository and Clearing Corporation (VSDC) is recognised on the record date. Dividend income from shares that have not been registered with VSDC is recognised when the right to receive dividend is established. Share dividends are not recognised as income. Dividends received which are attributable to the period before investment acquisition date are deducted from the carrying amount of the investment.

(p) Lease payments

Payments made under operating leases are recognised in the statement of income on a straight-line basis over the term of the lease.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(q) Production and business expenses

Expenses shall be recognised in the statement of income in the period in which they are incurred. Except where the expenses relate to the results of production and business activities of multiple accounting periods, they shall be allocated to the statement of income on a systematic or proportional basis.

(r) Borrowing costs

Borrowing costs are recognised as an expense in the period in which they are incurred, except where the borrowing costs relate to borrowings in respect of the construction of qualifying assets, in which case the borrowing costs incurred during the period of construction are capitalized as part of the cost of the assets concerned.

(s) Earnings per share

The Company presents basic and diluted earnings per share ("EPS") for its ordinary shares. Basic EPS is calculated by dividing the profit attributable to the ordinary shareholders (after deducting any amounts appropriated to bonus and welfare funds for the accounting period) of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting both the profit or loss attributable to the ordinary shareholders and the weighted average number of ordinary shares outstanding to reflect the effect of all dilutive potential ordinary shares, including convertible bonds and share options. During the period, the Company had no potential ordinary shares and therefore did not present diluted EPS.

(t) Segment reporting

A segment is a distinguishable component of the Company that is engaged either in providing related products or services (business segment), or in providing products or services within a particular economic environment (geographical segment), which is subject to risks and rewards that are different from those of other segments. The Board of General Directors believes that the Company operates primarily in a single business segment, namely the wholesale and retail trading of pharmaceuticals, medical instruments and supplies, cosmetics, and sanitary products, and in a single geographical segment, Vietnam, during the period.

(u) Related parties

A segment is a distinguishable component of the Company that is engaged either in providing related products or services (business segment), or in providing products or services within a particular economic environment (geographical segment), which is subject to risks and rewards that are different from those of other segments. The Company's primary format for segment reporting is based on business segments.

(v) Comparative information

Comparative information in these financial statements is presented as corresponding figures. Under this method, comparative information for the prior period are included as an integral part of the current period financial statements and are intended to be read only in relation to the amounts and other disclosures relating to the current period. Accordingly, the comparative information included in these financial statements is not intended to present the Company's financial position, results of operation or cash flows for the prior period.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

5. Cash and cash equivalents

	30/09/2026 VND	1/1/2026 VND (As Restated)
Cash on hand	294,846,878	123,263,854
Cash in banks	83,046,022,513	30,315,859,748
Military Commercial Joint Stock Bank – Ho Chi Minh City Branch	26,597,146,497	3,692,386,726
Vietnam International Commercial Joint Stock Bank – Ho Chi Minh City Branch	41,931,554,962	5,529,317,164
Other Banks	14,517,321,054	21,094,155,858
	83,340,869,391	30,439,123,602

6. Financial Investments

(a) Held-to-Maturity Investments

	Amortized Cost and Recoverable Amount	
	30/09/2026	1/1/2026
	VND	VND
Short-term time deposits	307,479,452	300,000,000

Short-term held-to-maturity investments comprise the principal amounts and accrued interest receivable on bank deposits with original maturities of more than 3 months and up to 12 months, detailed as follows:

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

		30/09/2026		01/01/2026	
		Term	Interest Rate	Term	Interest Rate
			VND		VND
Contract					
2025120900636431471	6 months	5.0 %	307,479,452	6 months	5.0 %
Short-term Held-to-Maturity Investments			307,479,452		300,000,000
					300,000,000



Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(b) Investments in Associates

Associate	Address	Principal Activities	30/09/2026 và 1/1/2026			
			Number of Shares Held	% of Capital Contribution	% of voting rights	% of equity owned
Alfresa Codupha Vietnam Healthcare Co., Ltd (*)	262L Le Van Sy Street, Nhieu Loc Ward, Ho Chi Minh City, Vietnam	Retail and Wholesale of Medical Products		30%	30%	30%

The carrying amounts and fair values of the companies as at September 30, 2026 and January 1, 2026 are as follows:

	30/09/2026		1/1/2026	
	Cost VND	Allowance VND	Recoverable amount VND	Recoverable amount VND
Alfresa Codupha Vietnam Healthcare Co., Ltd (*)	3,520,408,664		(*)	(*)
	<u>3,520,408,664</u>		<u>3,520,408,664</u>	

(*) The Company has not determined the fair value of these financial investments for disclosure in the interim financial statements because there are no quoted market prices for these investments, and the Vietnamese Accounting Standards and the Vietnamese Accounting Regime for Enterprises currently provide no guidance on determining fair value using valuation techniques. The fair values of these financial investments may differ from their carrying amounts.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(c) Investments in Other Entities

Other Entities	Number of Shares Held	% of Capital Contribution (**)	% of voting rights	Cost	Allowance	Recoverable amount	Number of Shares Held	% of Capital Contribution (**)	% of voting rights	Cost	Allowance	Recoverable amount
				VND	VND	VND				VND	VND	VND
Kingdom Indochina Joint Stock Company (i)		3.68%	0%	22,983,000,000		(*)		3.68%	0%	22,983,000,000		(*)
Indochina Urban Development Joint Stock Company (ii)		3.86%	0%	6,017,000,000		(*)		3.86%	0%	6,017,000,000		(*)
Tuyen Quang Pharmaceutical and Trading Services Joint Stock Company	43,000	0.86%	0.86%	472,484,723		(*)	43,000	0.86%	0.86%	472,484,723		(*)
				29,472,484,723						29,472,484,723		

(i) At the reporting date, the Company held 2,900,000 non-voting preference shares in these companies. These investments are assets pledged as collateral for the Company's long-term borrowings (Note 23(b)).

(*) The fair value of these investments as at September 30, 2026 has not been determined based on the trading prices of shares of companies listed on stock exchanges or traded on the market for unlisted public companies. The fair value of these financial investments may differ from their carrying amounts.

(**) The capital contribution percentage is calculated as the number of shares held by the Company divided by the total number of ordinary shares issued by the investee.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

7. Short-term Trade Receivables

	30/09/2026		1/1/2026	
	Carrying amount VND	Allowance VND	Carrying amount VND	Allowance VND
Other Parties				
An Vuong Pharmaceutical Company Limited	21,515,820,483	-	165,274,139,100	-
Khun Thang Pharmaceutical Company Limited	51,884,254,475	-	92,080,485,250	-
Bao Ngan Pharmaceutical Company Limited	56,888,207,280	-	23,814,000,000	-
Others	954,390,688,725	(57,396,308,585)	911,313,401,489	(45,758,977,426)
	1,084,678,970,963	(57,396,308,585)	1,192,482,025,839	(45,758,977,426)

8. Short-term Advances to Suppliers

	30/09/2026		1/1/2026	
	Carrying amount VND	Allowance VND	Carrying amount VND	Allowance VND
Other Parties				
KIM HUU TECHNICAL SERVICES TRADING COMPANY LIMITED	5,462,437,500		-	
HAI TIEN MEDICAL INVESTMENT TRADING COMPANY LIMITED	18,136,281,243		-	
NOAH LEGEND COMPANY LIMITED	3,766,670,666		3,361,370,685	
EURO HEALTHCARE PTE LTD	2,739,616,391		1,725,863,436	
Y,S,P INDUSTRIES (M) SDN, BHD	-		3,819,076,807	
EGIS PHARMACEUTICALS PLC	-		2,833,649,424	
WINDLAS BIOTECH LIMITED	12,162,838,556			
Other Prepayments	9,553,665,172		2,499,329,597	
	51,821,509,528		14,239,289,949	

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

9. Other receivables

(a) Other short-term receivables comprised:

	30/09/2026		1/1/2026	
	Carrying amount VND	Allowance VND	Carrying amount VND	Allowance VND
Business support receivables	9,466,621,764	-	23,099,820,484	-
Receivables from trade discounts	-	-	12,617,492,308	-
Receivables from support for the destruction of damaged goods	8,265,602,513	-	12,292,638,682	-
Phải thu thanh toán hộ	-	-	9,022,339,400	-
Receivables from early payment discounts	6,725,614,989	-	6,953,826,707	-
Receivables from distribution and warehousing support	6,160,375,602	(2,019,922,904)	5,859,642,748	(1,303,743,222)
Deposits	2,849,211,337	-	2,395,694,102	-
Receivables from entrusted imports	1,622,984,318	(1,615,418,822)	1,659,798,876	(1,615,418,822)
Deferred payment interest receivables	1,084,088,667	(995,448,795)	1,338,975,324	(995,448,795)
Advances to employees	2,668,248,990	-	1,200,776,401	-
Others	421,002,192	-	4,976,305,920	-
	39,263,750,372	(4,630,790,521)	81,417,310,952	(3,914,610,839)

(b) Other long-term receivables comprised:

	30/09/2026		1/1/2026	
	Carrying amount VND	Allowance VND	Carrying amount VND	Allowance VND
Deposits	776,000,000	-	650,000,000	-
	776,000,000	-	650,000,000	-

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

10. Bad and doubtful debts

	30/09/2026				1/1/2026			
	Overdue period	Cost VND	Allowance VND	Recoverable amount VND	Overdue period	Cost VND	Allowance VND	Recoverable amount VND
Short-term receivables from customers:								
Mi Nguyen Pharmaceutical Trading Company Limited	37-64 months	19,954,092,956	(19,954,092,956)	-	27-55 months	19,954,092,956	(19,954,092,956)	-
Hiep Bach Nien Pharmaceutical Joint Stock Company	Over 30 months	1,606,515,856	(1,208,782,583)	397,733,273	Over 24 months	2,634,126,445	(1,361,593,003)	1,272,533,442
Kim Chau Pharmaceutical Company Limited	Over 51 months	4,086,849,776	(4,086,849,776)	-	Over 48 months	4,086,849,776	(4,086,849,776)	-
Hoang An Medical Equipment Joint Stock Company	Over 51 months	2,908,892,308	(2,908,892,308)	-	Over 48 months	2,908,892,308	(2,908,892,308)	-
Asia Medical Food Company Limited	19 - 23 months	15,014,018,716	(15,014,018,716)	-	9 - 14 months	18,008,018,716	(6,624,312,090)	11,383,706,626
Gravitas Joint Stock Company	12 - 17 months	11,312,827,360	(5,318,803,375)	5,994,023,985	3 - 8 months	11,312,827,360	(2,887,432,751)	8,425,394,609
Ngoi Sao Foods Joint Stock Company	9 months	2,532,090,000	(759,627,000)	1,772,463,000	-	-	-	-
Others	6 - over 36 months	8,783,250,407	(8,145,241,871)	638,008,536	6 - over 36 months	10,745,267,822	(7,935,804,542)	2,809,463,280
		66,198,537,379	(57,396,308,585)	8,802,228,794		69,650,075,383	(45,758,977,426)	23,891,097,957

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

	Overdue period	30/09/2026			1/1/2026			
		Cost VND	Allowance VND	Recoverable amount VND	Overdue period	Cost VND	Allowance VND	Recoverable amount VND
Other receivables								
An Phat Pharmaceutical and Medical Equipment Joint Stock Company	Over 36 months	2,610,867,617	(2,610,867,617)	-	Over 36 months	2,610,867,617	(2,610,867,617)	-
Hai Dang Koko Construction Materials Import Export One Member Company Limited	Over 48 months	816,000,000	(816,000,000)	-	Over 36 months	816,000,000	(816,000,000)	-
Mi Nguyen Pharmaceutical Trading Company Limited	Over 48 months	487,743,222	(487,743,222)	-	Over 36 months	487,743,222	(487,743,222)	-
Xuan Vy Company Limited	Over 6 months	2,387,265,606	(716,179,682)	1,671,085,924				
		6,301,876,445	(4,630,790,521)	1,671,085,924		3,914,610,839	(3,914,610,839)	-
Prepayments to suppliers								
Hoang An Medical Equipment Joint Stock Company		-	-	-		216,106,684	(216,106,684)	-
		-	-	-		216,106,684	(216,106,684)	-
TOTAL		72,500,413,824	(62,027,099,106)	10,473,314,718		73,780,792,906	(49,889,694,949)	23,891,097,957

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

Movements in allowance for doubtful debts during the period were as follows:

	Nine-month period ended	
	30/09/2026	30/09/2025
	VND	VND
Opening balance	49,889,694,949	35,752,861,392
Allowance made during the period	12,628,482,289	8,323,146,841
Allowance reversed during the period	(491,078,132)	(3,190,498,290)
Closing balance	62,027,099,106	40,885,509,943

11. Inventories

	30/09/2026		1/1/2026	
	Carrying amount	Allowance	Carrying amount	Allowance
	VND	VND	VND	VND
Goods in transit	550,484,690	-	61,242,584,127	-
Merchandise inventories	1,013,412,050,741	(2,524,831,878)	884,717,783,151	(1,058,824,375)
	1,013,962,535,431	(2,524,831,878)	945,960,367,278	(1,058,824,375)

Movements in the allowance for inventories during the period were as follows:

	Nine-month period ended	
	30/09/2026	30/09/2025
	VND	VND
Opening balance	1,058,824,375	5,522,387,750
Allowance made during the period	5,895,274,969	12,387,969,820
Allowance reversed during the period	(4,075,609,539)	(4,032,956,721)
Allowance utilised during the period	(353,657,927)	(4,786,686,811)
Closing balance	2,524,831,878	9,090,714,038

12. Other assets

	30/09/2026	1/1/2026
	VND	VND
Term deposits at banks restricted for use (*)	8,100,000,000	-
	8,100,000,000	-

(*) Term deposits at banks are restricted for use as they are pledged to Vietnam International Commercial Joint Stock Bank (VIB) as collateral for the credit facility.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

13. Tangible fixed assets

Cost	Buildings and structures VND	Machinery and equipment VND	Motor vehicles VND	Office equipment VND	Others VND	Total VND
Opening balance	95,966,408,877	49,039,768,369	37,340,905,579	3,139,305,211	57,807,463	185,544,195,499
Purchases During the Period	-	428,550,185	-	412,748,704	-	841,298,889
Disposals						
Closing balance	95,966,408,877	49,468,318,554	37,340,905,579	3,552,053,915	57,807,463	186,385,494,388
Accumulated depreciation						
Opening balance	41,475,570,021	39,513,940,437	26,116,715,558	2,804,824,930	57,807,463	109,968,858,409
Charge for the period	3,240,770,526	3,015,342,311	1,630,664,048	179,234,865	-	8,066,011,750
Disposals						
Closing balance	44,716,340,547	42,529,282,748	27,747,379,606	2,984,059,795	57,807,463	118,034,870,159
Net book value						
Opening balance	54,490,838,856	9,525,827,932	11,224,190,021	334,480,281	-	75,575,337,090
Closing balance	51,250,068,330	6,939,035,806	9,593,525,973	567,994,120	-	68,350,624,229

Included in tangible fixed assets were assets costing VND 42,448 million which were fully depreciated as at 30 September 2026 (1/1/2026: VND 41,289 million), but which are still in active use.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

Major tangible fixed assets in use:

	Cost	
	30/9/2026 VND	1/1/2026 VND
Warehouse - Le Minh Xuan Industrial Park	58,197,850,115	58,197,850,115
Office Building and GSP Warehouse	12,543,758,862	12,543,758,862
	70,741,608,977	70,741,608,977

14. Intangible fixed assets

	Land use rights VND	Software VND	Total VND
Cost			
Opening balance	95,082,437,845	2,621,966,000	97,704,403,845
Closing balance	95,082,437,845	2,621,966,000	97,704,403,845
Accumulated depreciation			
Opening balance	20,138,601,930	1,771,776,070	21,910,378,000
Charge for the period	1,904,754,771	253,099,903	2,157,854,674
Closing balance	22,043,356,701	2,024,875,973	24,068,232,674
Net book value			
Opening balance	74,943,835,915	850,189,930	75,794,025,845
Closing balance	73,039,081,144	597,090,027	73,636,171,171

Included in intangible fixed assets were assets costing VND 558.67 million which were fully amortised as at 30 September 2026 (1/1/2026: VND 558.67 million), but which are still in use.

The intangible fixed assets are primarily in use:

	Cost	
	30/09/2026 VND	1/1/2026 VND
Land Use Rights – Le Minh Xuan Industrial Park	47,797,852,740	47,797,852,740
Land Use Rights – Can Tho	35,338,885,449	35,338,885,449
	83,136,738,189	83,136,738,189

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

15. Construction in progress

Major constructions in progress were as follows:

	30/09/2026 VND	1/1/2026 VND
Inventory and sales management software	231,000,000	390,900,000
Others	150,000,000	150,000,000
	381,000,000	540,900,000

16. Long-term Prepaid Expenses

	Prepaid Land Costs VND	Tools and Supplies VND	Warehouse and Office Repair Expenses VND	Total VND
Opening Balance		14,685,164	1,890,310,536	1,904,995,700
Additions During the Period			66,051,380	66,051,380
Amortization During the Period		(14,685,164)	(1,431,868,960)	(1,446,554,124)
Closing Balance		-	524,492,956	524,492,956

17. Deferred Income Tax Assets

	Tax Rate	30/09/2026 VND	1/1/2026 VND
Overdue Receivables from ASIA MEDICAL FOOD Company Limited	20%	1,202,001,872	-
		1,202,001,872	-

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

18. Accounts payable to suppliers

Accounts payable to suppliers detailed by significant suppliers:

	30/09/2026	1/1/2026
	VND	VND
Related parties	875,553,326	1,065,634,897
Alfresa Codupha Vietnam Healthcare Co., Ltd. – an associate	875,553,326	875,553,313
Central Pharmaceutical Joint Stock Company No. 3 – fellow subsidiary within the Group	-	190,081,584
Other parties	978,784,971,349	1,144,229,251,867
Hisamitsu Vietnam Pharmaceutical Co., Ltd	413,977,959,795	252,765,103,748
Novapri Lifescience Private Limited	5,456,918,172	162,930,176,208
Prime Pharmaceuticals Ltd	54,222,230,280	94,523,915,122
Others	505,127,863,102	634,010,056,789
	979,660,524,675	1,145,294,886,764

19. Short-term Advances from Customers

	30/09/2026	1/1/2026
	VND	VND
Other parties		
- Truong Ton Pharmaceutical Trading Company Limited	378,677,860	5,052,302,300
- Ngoc My International Trading Company Limited	7,805,991,331	4,468,351,745
- Tin Duc Pharmaceutical Company Limited	-	3,105,000,000
- An Duoc Pharmaceutical Joint Stock Company	-	3,835,371,185
- SHANDONG GUOXIN IMPORT & EXPORT CO.,LTD	639,761,580	3,015,255,081
- Tay Ninh Provincial Department of Health		3,881,800,000
- An Giang Provincial Department of Health	22,459,800,000	-
- Civil and Industrial Construction Investment Project Management Board	45,060,800,000	-
- Dong Thap Provincial Civil and Industrial Construction Investment Project Management Board	18,601,314,000	-
- Other	13,717,513,632	2,642,209,958
	108,663,858,403	26,000,290,269

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

20. Taxes and others receivable from and payable to the State

	1/1/2026		Số phát sinh trong kỳ			30/09/2026	
	Receivable VND	Payable VND	Payable VND	Deducted VND	Paid VND	Receivable VND	Payable VND
Value added tax on domestic goods	-	(11,584,288)	(112,836,097,746)	111,295,584,035	1,448,851,376	-	(103,246,623)
Value added tax on imports	167,318,390	-	(20,973,657,979)	-	22,207,208,605	1,400,869,016	-
Import-export tax	-	-	(1,170,091,012)	-	2,534,453,765	1,364,362,753	-
Corporate income tax	-	(347,856,799)	(6,653,657,739)	-	4,806,510,522	-	(2,195,004,016)
Personal income tax	-	(159,298,485)	(527,485,849)	339,974,262	261,184,474	-	(85,625,598)
Land Use Tax	-	-	(4,091,789)	-	4,091,789	-	-
Other Fees and Charges	-	-	-	-	-	-	-
	167,318,390	(518,739,572)	(142,165,082,114)	111,635,558,297	31,262,300,531	2,765,231,769	(2,383,876,237)

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

21. Accrued expenses

	30/09/2026 VND	1/1/2026 VND
Interest expense	4,360,430,095	1,670,000,000
Purchased Services Expenses	357,150,000	825,961,288
Employee Expenses	556,710,000	513,851,349
Others	480,382,472	443,688,980
	5,754,672,567	3,453,501,617

22. Other payables

	30/09/2026 VND	1/1/2026 VND
Payables relating to entrusted import transactions	1,737,176,618	1,090,370,147
Short-term deposits and collaterals received	739,006,586	1,621,541,128
Others	10,162,969,547	2,013,823,465
	12,639,152,751	4,725,734,740

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

23. Borrowings

(a) Short-term borrowings

	1/1/2026	Phát sinh trong kỳ		30/09/2026
	Carrying amount VND	Addition VND	Decrease VND	Carrying amount VND
Loans from Individuals (i)	100,000,000	-	100,000,000	-
Short-term Bank Borrowings (ii)	963,346,289,022	2,206,326,140,137	2,132,827,769,641	1,036,844,659,518
Long-term debt	29,000,000,000	-	-	29,000,000,000
	992,446,289,022	2,206,326,140,137	2,132,927,769,641	1,065,844,659,518

(i) The terms of the outstanding short-term loans from individuals are as follows:

Lender	Currency	Annual interest rate	30/09/2026 VND	1/1/2026 VND
Loans from Employees	VND	5%	-	100,000,000
			-	100,000,000

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(ii) The terms and conditions of the outstanding short-term bank borrowings are as follows:

Lender	Currency	Annual interest rate	30/09/2026	1/1/2026	Security Terms
			VND	VND	
Short-term Borrowings: (VND) - HCM - ACB.CN PHU LAM	VND	(7.9% Fixed 4M + (Base Interest Rate +2.8%) 2M)	99,934,653,408		- Receivables arising from contracts entered into between the Company and its customers, with a value of VND 120,000,000,000.
Short-term Borrowings: (VND) - HCM - VIETINBANK HCM	VND	8.00% - 8.20%	425,971,013,385	449,152,811,079	Receivables arising from contracts entered into between the Company and its customers, with a value of VND 280,000,000,000, and a portion of slow-moving inventory valued at VND 240,000,000,000.
Short-term Borrowings: (VND) - HCM - MB BANK CN SGON	VND	7.50% - 8.80%	184,219,673,730	291,923,006,262	- Receivables arising from contracts entered into between the Company and its customers, valued at VND 250,000,000,000, and a portion of inventory valued at VND 250,000,000,000. - Property located at Land Parcel No. 76, Map Sheet No. 13, No. 132A Nguyen Van Cu Noi Dai Street, Tan An Ward, Can Tho City (formerly No. 132A Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City).
Short-term Borrowings: (VND) - HCM - SHINHAN BANK	VND	7.50% - 8.57%	45,994,775,746	50,000,000,000	Receivables arising from contracts entered into between the Company and its customers, valued at VND 50,000,000,000.
Short-term Borrowings: (VND) - HCM - SHB	VND	(7.7% Fixed 3M + (Base Interest Rate +3%) 3M)	50,038,237,305	-	Unsecured

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

Short-term Borrowings: (VND) - HCM - VIB BANK HCM	VND	8.75%	224,952,365,556	172,270,471,681	“Unsecured revolving inventory with a value of VND 250,000,000,000 and revolving receivables with a value of VND 250,000,000,000; Deposit contract issued by VIB with a value of VND 8,100,000,000.”
Short-term Borrowings: (VND) - HA NOI - VIETINBANK TX	VND	8.00%	5,733,940,388	-	Revolving inventory owned by the Company at Lot No. 9, Yen Nghia Industrial Park, Ha Dong District, Hanoi, with a total value of VND 62,000,000,000, and receivables or revolving rights to claim debts arising from receivables, with a total value of VND 78,000,000,000.

(b) Long-term borrowings

	1/1/2026 Carrying amount VND	Phát sinh trong kỳ		30/09/2026 Carrying amount VND
		Addition VND	Decrease VND	
Hoa Lam Investment Development Corporation	29,000,000,000	-	-	29,000,000,000
Current Portion Due Within 12 Months	29,000,000,000	-	-	29,000,000,000

The long-term loan from Hoa Lam Investment Development Joint Stock Company is interest-free, matures in 2027, and is secured by the investments in Dong Duong Urban Development Joint Stock Company and Kingdom Dong Duong Joint Stock Company (Note 6(c)).

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

24. Bonus and welfare funds

	Six-month period ended	
	30/09/2026	30/09/2025
	VND	VND
Opening balance	-	1,648,607,002
Appropriation from retained profits after tax	6,746,427,497	1,231,482,227
Utilisation	(4,426,238,317)	(2,880,089,229)
Other Increases/Decreases	(978,048,437)	-
Closing balance	1,342,140,743	-

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

25. Changes in owners' equity

	Share Capital VND	Repurchased own shares VND	Investment and development fund VND	Retained profits VND	Total VND
Balance at 1 January 2025	182,700,000,000	(586,200,000)	9,071,115,794	30,262,853,739	221,447,769,533
Net profit for the period				20,930,801,305	20,930,801,305
Dividends				(16,387,920,000)	(16,387,920,000)
Appropriation to bonus and welfare funds				(1,231,482,226)	(1,231,482,226)
Balance at 30 September 2025	182,700,000,000	(586,200,000)	9,071,115,794	33,574,252,818	224,759,168,612
Balance at 01 January 2026	182,700,000,000	(586,200,000)	9,071,115,794	36,096,114,822	227,281,030,616
Net profit for the period				21,198,822,223	21,198,822,223
Dividends (*)				(9,104,400,000)	(9,104,400,000)
Appropriation to bonus and welfare funds (*)				(6,746,427,497)	(6,746,427,497)
Balance at 30 September 2026	182,700,000,000	(586,200,000)	9,071,115,794	41,44,109,548	232,629,025,342

(*) The Company distributed dividends and appropriated amounts to the Development Investment Fund and the Bonus and Welfare Fund from its 2025 profit after tax, pursuant to the Resolution of the Company's General Meeting of Shareholders.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

26. Share capital

The Company's authorised and issued share capital are:

	30/09/2026		1/1/2026	
	Number of shares	Amount VND	Number of shares	Amount VND
Authorised share capital	18,270,000	182,700,000,000	18,270,000	182,700,000,000
Issued share capital				
Ordinary shares	18,270,000	182,700,000,000	18,270,000	182,700,000,000
Repurchased own shares				
Ordinary shares	(61,200)	(586,200,000)	(61,200)	(586,200,000)
Shares in circulation				
Ordinary shares	18,208,800	182,113,800,000	18,208,800	182,113,800,000

All ordinary shares have a par value of VND10,000. Each share is entitled to one vote at meetings of the Company. Shareholders are entitled to receive dividend as declared from time to time. All ordinary shares are ranked equally with regard to the Company's residual assets. In respect of shares repurchased by the Company, all rights are suspended until those shares are reissued.

Major shareholders of the Company were as follows:

	30/09/2026		1/1/2026	
	VND	%	VND	%
Vietnam Pharmaceutical Corporation	121,225,000,000	66.35%	121,225,000,000	66.35%
NTP Fund Management Joint Stock Company	15,076,500,000	8.25%	-	-
DSC Securities Corporation	27,163,900,000	14.87%	-	-
Ben Tre Pharmaceutical Joint Stock Company	-	-	34,700,000,000	19.00%
Other shareholders	19,234,600,000	10.53%	26,775,000,000	15.00%
	182,700,000,000	100%	182,700,000,000	100%

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

27. Off statement of financial position items

(a) Lease

The Company as a Lessee

The future minimum lease payments under non-cancellable operating leases were:

	30/09/2026 VND	1/1/2026 VND
Less than 1 year	7,089,552,000	4,215,000,000
From 1 to 5 years	16,028,244,000	10,116,000,000
	23,117,796,000	14,331,000,000

Leased assets under operating leases comprise:

	Lease term	30/09/2026 VND	1/1/2026 VND
Building at 262L Le Van Sy, Nhieu Loc Ward, Ho Chi Minh City, Vietnam	1 năm	3,960,000,000	3,870,000,000
Building at 262L Le Van Sy, Nhieu Loc Ward, Ho Chi Minh City, Vietnam	3 năm	6,336,000,000	9,306,000,000
Building at No. 16, Plot C2/NO, Nam Trung Yen Area, Yen Hoa Ward, Hanoi City, Vietnam	1 năm	756,000,000	-
Building at No. 16, Plot C2/NO, Nam Trung Yen Area, Yen Hoa Ward, Hanoi City, Vietnam	5 năm	2.608,200,000	-
Building at No. 42, Lot 09, Yen Nghia Industrial Cluster, Quyet Thang Street, Yen Nghia, Hanoi City, Vietnam	1 năm	2,013,552,000	-
Building at No. 42, Lot 09, Yen Nghia Industrial Cluster, Quyet Thang Street, Yen Nghia, Hanoi City, Vietnam	5 năm	6,544,044,000	-
Building at No. 18, Lot 11B, Tran Van Giang Street, Hai An Ward, Hai Phong City, Vietnam	1 năm	360,000,000	345,000,000
Building at No. 18, Lot 11B, Tran Van Giang Street, Hai An Ward, Hai Phong City, Vietnam	3 năm	540,000,000	810,000,000
		23,117,796,000	14,331,000,000

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(b) Foreign currencies

	30/09/2026		1/1/2026	
	Original currency	VND equivalent	Original currency	VND equivalent
USD	9,781	255,822,851	102,278	2,697,794,193
EUR	920	27,430,221	937	29,688,981
		<u>283,253,072</u>		<u>2,727,483,174</u>

(c) Goods held for third parties

	30/09/2026 Quantity	1/1/2026 Quantity
<i>Bottles</i>	6,522	78,613
<i>Sachets</i>	1,550	46,410
<i>Boxes</i>	853,896	757,802
<i>Ampoules</i>	32,900	124,567
<i>Tubes</i>	1,687	93,809
<i>Others</i>	11,045	51,889

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

28. Revenue from sales of goods and provision of services

Total revenue from sales of goods and provision of services represents the gross value of goods sold and services rendered exclusive of value added tax.

Net revenue from sales of goods and provision of services comprised:

	Nine-month period ended	
	30/09/2026	30/09/2025
	VND	VND
Total revenue		
• Sales	1,961,904,429,837	2,218,470,420,530
• Services and Leases	40,514,113,751	38,809,330,858
	2,002,418,543,588	2,257,279,751,388
Less revenue deductions		
• Sales returns	21,707,574,844	11,882,942,182
• Sales allowances	71,407,712	1,530,449,415
	21,778,982,556	13,413,391,597
Net revenue from sales of goods and provision of services	1,980,639,561,032	2,243,866,359,791

29. Cost of sales

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Goods sold	1,777,736,870,646	2,080,804,842,915
Services rendered and rental services provided	21,165,096,217	3,376,572,336
Allowance for inventories	1,819,665,430	8,355,013,099
	1,800,721,632,293	2,092,536,428,350

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

30. Financial income

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Interest income from deposits	31,772,897	23,626,677
Realised foreign exchange gains	8,830,393,252	8,914,958,049
Unrealised foreign exchange gains	1,686,949,627	2,893,627,717
Interest income from credit sales	1,195,526,700	4,289,284,874
Early payment discounts received	8,828,463,171	7,940,468,241
	20,573,105,647	24,061,965,558

31. Financial expenses

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Interest expense	55,533,279,847	33,184,367,292
Realized Foreign Exchange Losses	2,364,615,630	7,018,298,643
Others	-	117,465,809
	57,897,895,477	40,320,131,744

32. Selling expenses

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Staff costs	46,545,244,684	46,473,526,526
Raw material costs	1,048,737,544	1,755,654,125
Depreciation and amortisation	8,727,195,407	9,050,730,031
Outside services	17,492,903,557	14,120,161,460
Others	15,839,754,296	15,416,465,091
	89,653,835,488	86,816,537,233

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

33. General and administration expenses

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Staff costs	2,509,107,637	2,506,772,725
Office equipment and supplies	441,716,167	862,564,850
Depreciation and amortisation	1,496,671,017	1,342,952,838
Provision/(reversal) of allowance for doubtful debts	12,137,404,157	5,132,648,551
Outside services	6,119,872,531	8,920,533,183
Others	2,077,512,611	7,578,063,538
	24,782,284,120	26,343,535,685

34. Production and business costs by element

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Goods costs	1,777,736,870,646	2,080,804,842,915
Raw material costs	1,490,453,711	2,618,218,975
Staff costs	49,054,352,321	48,980,299,251
Depreciation and amortisation	10,223,866,424	10,393,682,869
Provision/(reversal) of allowance for doubtful debts	12,137,404,157	5,132,648,551
Outside services	23,612,776,088	23,040,694,643
Others	17,917,266,907	22,994,528,629
	1,892,172,990,254	2,193,964,915,833

35. Other Income

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Gain on Disposal of Fixed Assets	2.222.222	709.148.468
Others	857.541.701	3.837.325.000
	859.763.923	4.546.473.468

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

36. Other Expenses

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Administrative Penalties	186,021,755	200,448,172
Others	2,180,283,380	226,964,553
	2,366,305,135	427,412,725

37. Income tax

(a) Recognised in the interim statement of income

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Income tax expense – current		
Current period	6,625,887,138	5,099,951,775
Prior years' corporate income tax adjustment	27,770,600	-
	6,653,657,738	5,099,951,775
Income tax benefit – deferred		
Origination of temporary differences	(1,202,001,872)	-
	5,451,655,866	5,099,951,775

(b) Reconciliation of effective tax rate

	Nine-month period ended	
	30/09/2026	30/09/2026
	VND	VND
Accounting profit before tax	26,650,478,089	26,030,753,080
Tax at the Company's tax rate	5,330,095,618	5,206,150,616
Non-deductible expenses	93,789,648	116,482,505
Non-Taxable Income	-	(222,681,346)
Unrecognised temporary differences	-	-
Under-provisioning in Previous Years	27,770,600	-
	5,451,655,866	5,099,951,775

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

(c) Applicable tax rates

Under the Law on Corporate Income Tax, the Company has an obligation to pay the government income tax at the rate of 20% of taxable profits.

(d) Recognized Deferred Income Tax Assets

	Tax Rate	30/09/2026 VND	1/1/2026 VND
Deferred Income Tax Assets			
Provision for Doubtful Receivables	20%	1,202,001,872	-
		1,202,001,872	-

38. Basic earnings per share

The calculation of basic earnings per share for the six-month period ended 30 September 2026 was based on the net profit attributable to ordinary shareholders of the parent company, after deducting the amounts appropriated to bonus and welfare funds for the nine-month period ended 30 September 2026 of VND 17,806 million (nine-month period ended 30 September 2025: VND 16,000 million) and a weighted average number of ordinary shares outstanding of 18,208,800 (nine-month period ended 30 September 2025: 18,208,800), calculated as follows:

	Nine-month period ended	
	30/09/2026 VND	30/09/2026 VND (As Restated)
Net profit for the period	21,198,822,223	20,930,801,305
Appropriation to bonus and welfare funds	3,393,114,512	4,930,451,587
Net profit attributable to ordinary shareholders	17,805,707,711	16,000,349,718
Weighted average number of ordinary shares	18,208,800	18,208,800
Basic Earnings per Share (Basic EPS)	978	879

As at the reporting date, the Company estimated the amount of profit for the nine-month period ended September 30, 2026 to be allocated to the Bonus and Welfare Fund based on the 2026 plan approved by the 2026 Annual General Meeting of Shareholders..

The profit after tax attributable to ordinary shareholders for the nine-month period ended September 30, 2025 has been restated to reflect the appropriation to the Bonus and Welfare Fund for 2025, as approved by the 2026 Annual General Meeting of Shareholders.

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

Basic earnings per share for the nine-month period ended September 30, 2025 have been restated as follows:

	Nine-month period ended 30/09/2025	
	Net Profit Attributable to Ordinary Shareholders VND	Basic Earnings per Share VND
Previously Reported Amount	17,180,801,305	944
Effect of the Adjustment to the Appropriation to the Bonus and Welfare Fund	-1,180,451,587	-65
Restated Amount	<u>16,000,349,718</u>	<u>879</u>

39. Significant transactions with related parties

In addition to related party balances disclosed in other notes to the interim financial statements, the Company had the following significant transactions with related parties during the period:

	Transaction value	
	Nine-month period ended 30/09/2026 VND	30/09/2026 VND
Vietnam Pharmaceutical Corporation		
Dividends Paid	10,910,250,000	10,910,250,000
Ben Tre Pharmaceutical Joint Stock Company		
Dividends Paid	1,388,000,000	3,123,000,000
NTP Fund Management Joint Stock Company		
Dividends Paid	753,825,000	-
DSC Securities Joint Stock Company		
Dividends Paid	1,358,195,000	-

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

Key management personnel compensation

	Nine-month period ended	
	30/09/2026 VND	30/09/2026 VND
Board of Management		
Ông Lê Văn Sơn - Chủ tịch		720,000,000
Mr. Bui Huu Hien – Chairman	720,000,000	45,000,000
Ms. Pham Thi Mai Huong – Member	45,000,000	-
Ms. Lu Thi Khanh Tran – Member	45,000,000	45,000,000
Mr. Nguyen Quoc Hung – Member (from 22 April 2026)	25,000,000	-
Ms. Nguyen Thi Hang – Member (from 22 April 2026)	25,000,000	-
Ms. Ha Lan Anh – Member (until 21 April 2026)	20,000,000	45,000,000
Mr. Pham Thu Trieu – Member (until 21 April 2026)	20,000,000	45,000,000
Board of General Directors		
Ms. Pham Thi Mai Huong – General Director	675,000,000	409,090,909
Ms. Nguyen Thi Thuy Huong – Deputy General Director	495,000,000	232,500,000
Ms. Đinh Thị Khởi - Deputy General Director (until 1 March 2025)	-	110,000,000
Supervisory Board		
Mr. Nguyen Duc Tuan – Head of the Supervisory Board (from 22 April 2026 to 07 September 2026)	32,000,000	-
Ms. Nguyen Thi Thu Suong - Head of the Supervisory Board (from 07 September 2026)	8,000,000	-
Mr. Nguyen Van Dang – Member (from 07 September 2026)	2,000,000	-
Ms. Nguyen Thanh Thanh Binh – Member (to 07 September 2026)	16,000,000	18,000,000
Mr. Bach Quoc Vinh – Member (from 21 April 2026)	10,000,000	-
Ms. Nguyen Thi Hang – Head of the Supervisory Board (until 21 April 2026)	20,000,000	45,000,000
Mr. Truong Chi Thien – Member (until 21 April 2026)	8,000,000	18,000,000
Chief Accountant		
Mr. Nguyen Trieu Ngoc Thuan (until 25 August 2025)	-	360,000,000
Mr. Pham Chi Truc (from 25 August 2025 to 25 August 2026)	386,363,637	72,727,272

Codupha Central Pharmaceutical Joint Stock Company

Notes to the Financial Statements for the Nine-Month Period Ended 30 September 2026

40. Comparative Information

Unless otherwise disclosed, the comparative information as at January 1, 2026 is carried forward from the figures presented in the Company's financial statements as at December 31, 2025 and the Company's interim financial statements for the nine-month period ended September 30, 2026.

As disclosed in Note 3, effective January 1, 2026, the Company adopted Circular No. 99 and changed certain accounting policies on a prospective basis. Certain comparative figures have been reclassified to conform with the requirements of Circular No. 99 regarding the presentation of financial statements. The comparative table showing the figures as previously presented and as reclassified is set out below:

Statement of Financial Position

		1/1/2026	1/1/2026
	Mã số	(Đã trình bày lại)	(Theo báo cáo trước đây)
		VND	VND
Cash and Cash Equivalents	110	30,439,123,602	30,939,509,692
Other Current Assets	165	500,386,090	
Dividends and Profits Payable	313	7,311,946,476	
Other Short-term Payables	320	4,725,734,742	12,037,681,218

Authorized on October 19, 2026


Phạm Thị Mai Hương
General Director

Approver


Ngo Thi Bich Thao
Responsible for accounting and
financial reporting

Prepared by


Chu Thi Bich Hong
Deputy Finance and Accounting
Director